Company Valuation: Thiogenesis Therapeutics, Corp.

Data adjusted to current consolidation scope
Fiscal Period: December 2022 2023 2024 2025
Market Cap 1 22.54 33.43 27.61 33.69
Change - 48.3% -17.4% 22.03%
Enterprise Value (EV) 1 16.34 26.35 23.76 32.08
Change - 61.23% -9.83% 34.99%
P/E -3.74x -5.8x -8.65x -4.25x
PBR 3.77x 6.04x 8.06x 58.7x
PEG -0x 0.3x 0.2x -0x
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / EBIT -8.14x -5.06x -6.64x -4.34x
EV / FCF - - - -
FCF Yield - - - -
Dividend per Share 3 - - - -
Rate of return - - - -
EPS 3 -0.1552 -0.1294 -0.0693 -0.1528
Distribution rate - - - -
Net sales - - - -
EBITDA - - - -
EBIT 1 -2.009 -5.206 -3.579 -7.395
Net income 1 -3.924 -5.063 -3.146 -7.426
Net Debt 1 -6.196 -7.076 -3.848 -1.616
Reference price 3 0.5800 0.7500 0.6000 0.6500
Nbr of stocks (in thousands) 38,862 44,571 46,017 51,836
Announcement Date 4/28/23 4/29/24 4/25/25 4/30/26
1CAD in Million2USD in Million3CAD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
30.11x5.34x16.53x1.09% 43.13B
-20.5x304.3x-18.74x-.--% 34.65B
40.3x4.01x25.68x-.--% 30.03B
20.41x2.41x10.42x-.--% 28B
28.67x7.42x19.09x0.44% 24.45B
27x4.32x19.66x-.--% 13.14B
21.71x1.89x8.32x1.23% 12.53B
-20.52x13.52x-20.12x-.--% 12.25B
Average 15.90x 42.90x 7.61x 0.34% 24.77B
Weighted average by Cap. 17.39x 57.47x 8.63x 0.37%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. TTI Stock
  4. TTIPF Stock
  5. Valuation Thiogenesis Therapeutics, Corp.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!